<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515605</url>
  </required_header>
  <id_info>
    <org_study_id>MoMoTxRes</org_study_id>
    <nct_id>NCT01515605</nct_id>
  </id_info>
  <brief_title>Molecular Biological and Moleculargenetic Monitoring of Therapy After Kidney Transplantation</brief_title>
  <acronym>MoMoTxRes</acronym>
  <official_title>Molecular Biological and Moleculargenetic Monitoring of Therapy After Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Molecular monitoring is conducted in blood cells, plasma samples, urine samples and/or tissue&#xD;
      from patients after kidney transplantation. In the present study the investigators examine&#xD;
      the hypothesis that noninvasive diagnostic molecular monitoring can improve the outcome after&#xD;
      transplantation.&#xD;
&#xD;
      Routine clinical and laboratory data from serum and urine are evaluated at baseline and after&#xD;
      0-1-2-3-4-12-16-52 weeks and 1-2-3-4-5-6-7-8-9-10 years after kidney transplantation.&#xD;
      Mononuclear cells were obtained from the blood and transcripts of several diagnostic genes&#xD;
      (including GATA3 (Trans-acting T-cell-specific transcription factor3), GATA4 (Trans-acting&#xD;
      T-cell-specific transcription factor4), GAPDH (Glyceraldehyde 3-phosphate dehydrogenase),&#xD;
      TRPC3 (Transient receptor potential cononical type3), TRPC6 (Transient receptor potential&#xD;
      cononical type6), granzyme B, perforin, FOXP3 (Forkhead box P3), ISG15 (Interferon-stimulated&#xD;
      gene 15), Mx1 (Interferon-induced GTP-binding protein), MMP3 (Matrix metalloproteinase-3),&#xD;
      MMP9 (Matrix metalloproteinase-9), long-non-coding RNA, and others) are quantified using&#xD;
      standard quantitative RT-PCR (Reverse transcription polymerase chain reaction) techniques.&#xD;
      Proteomic analysis were performed in plasma and urine samples. Polymorphisms of selected&#xD;
      genes are analyzed using standard techniques. Data are analyzed by descriptive statistics.&#xD;
      Differences between groups were analyzed using Mann-Whitney test or Kruskal-Wallis-test and&#xD;
      Dunn's multiple comparison post-test, as appropriate. Associations between variables are&#xD;
      analyzed using regression analyses. Contingency tables are analyzed using Fisher's exact&#xD;
      test.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Molecular monitoring is conducted in blood cells, plasma samples, urine samples and/or tissue&#xD;
      from recipients after kidney transplantation and donors. In the present study the&#xD;
      investigators examine the hypothesis that noninvasive diagnostic molecular monitoring can&#xD;
      improve the outcome after transplantation.&#xD;
&#xD;
      Routine clinical and laboratory data from serum and urine are evaluated at baseline and after&#xD;
      0-1-2-3-4-12-16-52 weeks and 1-2-3-4-5-6-7-8-9-10 years, after kidney transplantation.&#xD;
      Mononuclear cells were obtained from the blood and transcripts of several diagnostic genes&#xD;
      (including GATA3 (Trans-acting T-cell-specific transcription factor3), GATA4 (Trans-acting&#xD;
      T-cell-specific transcription factor4), GAPDH (Glyceraldehyde 3-phosphate dehydrogenase),&#xD;
      TRPC3 (Transient receptor potential cononical type3), TRPC6 (Transient receptor potential&#xD;
      cononical type6), granzyme B, perforin, FOXP3 (Forkhead box P3), ISG15 (Interferon-stimulated&#xD;
      gene 15), Mx1 (Interferon-induced GTP-binding protein), MMP3 (Matrix metalloproteinase-3),&#xD;
      MMP9 (Matrix metalloproteinase-9), long-non-coding RNA, and others) are quantified using&#xD;
      standard quantitative RT-PCR (Reverse transcription polymerase chain reaction) techniques.&#xD;
      Proteomic analysis were performed in plasma and urine samples. Polymorphisms of selected&#xD;
      genes are analyzed using standard techniques.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2011</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cellular transcripts</measure>
    <time_frame>Day1</time_frame>
    <description>Transcripts and protein</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular transcripts</measure>
    <time_frame>Day8</time_frame>
    <description>Transcripts and protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular transcripts</measure>
    <time_frame>Day15</time_frame>
    <description>Transcripts and protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular transcripts</measure>
    <time_frame>Day22</time_frame>
    <description>Transcripts and protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular transcripts</measure>
    <time_frame>Day29</time_frame>
    <description>Transcripts and protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma proteome</measure>
    <time_frame>Day1</time_frame>
    <description>Plasma Proteome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma proteome</measure>
    <time_frame>Day8</time_frame>
    <description>Plasma proteome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma proteome</measure>
    <time_frame>Day15</time_frame>
    <description>Plasma proteome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma proteome</measure>
    <time_frame>Day22</time_frame>
    <description>Plasma proteome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma proteome</measure>
    <time_frame>Day29</time_frame>
    <description>Plasma proteome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine proteome</measure>
    <time_frame>Day1</time_frame>
    <description>Urine proteome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine proteome</measure>
    <time_frame>Day8</time_frame>
    <description>Urine proteome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine proteome</measure>
    <time_frame>Day15</time_frame>
    <description>Urine proteome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine proteome</measure>
    <time_frame>Day22</time_frame>
    <description>Urine proteome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine proteome</measure>
    <time_frame>Day29</time_frame>
    <description>Urine proteome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of kidney function, glomerular filtration rate, infections, therapy</measure>
    <time_frame>Day29</time_frame>
    <description>Association of kidney function, glomerular filtration rate, infections, therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of kidney function, glomerular filtration rate, infections, therapy</measure>
    <time_frame>Month6</time_frame>
    <description>Association of kidney function, glomerular filtration rate, infections, therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of kidney function, glomerular filtration rate, infections, therapy</measure>
    <time_frame>Month12</time_frame>
    <description>Association of kidney function, glomerular filtration rate, infections, therapy</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Transplantation Infection</condition>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Patients after kidney transplantation</arm_group_label>
    <description>Patients after kidney transplantation</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine, tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Kidney transplantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients after kidney transplantation, male, female, informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Deny of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Tepel, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <state>DK</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Tepel, Dr</last_name>
      <phone>4565503755</phone>
      <email>mtepel@health.sdu.dk</email>
    </contact>
    <contact_backup>
      <last_name>Martin Tepel, Dr</last_name>
      <phone>4565503755</phone>
      <email>martin.tepel@rsyd.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Tepel, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>January 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Martin Tepel</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

